First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC), ...
Dec 20, 2022
0
31
The microenvironment surrounding tumors in HER2+ breast cancer protects them and helps them develop resistance to the most widely used treatment, the monoclonal antibody trastuzumab. And a particular type of cell in this ...
Oct 14, 2022
0
80
An Austrian study led by MedUni Vienna showed that active brain metastases in breast cancer patients are partially or even completely regressed by a novel class of drug. This is a chemical conjugate of an antibody and a chemotherapy ...
Aug 9, 2022
0
945
